Last update 08 May 2025

PRDX3 x FOXM1 x 50S subunit

Basic Info

Related Targets
PRDX3FOXM150S subunit

Related

1
Drugs associated with PRDX3 x FOXM1 x 50S subunit
Thiostrepton
Target
50S subunit x FOXM1 x PRDX3
Mechanism
50S subunit inhibitors [+2]
Active Org.
RS Oncology LLCRS Oncology LLC [+2]
Originator Org.
RS Oncology LLCRS Oncology LLC
Active Indication
Metastatic breast cancer [+7]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with PRDX3 x FOXM1 x 50S subunit
NCT05278975
/ RecruitingPhase 1/2
A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
100 Clinical Results associated with PRDX3 x FOXM1 x 50S subunit
Login to view more data
100 Translational Medicine associated with PRDX3 x FOXM1 x 50S subunit
Login to view more data
0 Patents (Medical) associated with PRDX3 x FOXM1 x 50S subunit
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free